Charles River, Lundbeck in deal to use Logica for neurological disease drugs

Charles River Laboratories announced an agreement with H. Lundbeck o utilize Logica to progress critical brain disease research. “We are excited to partner with Lundbeck as they work toward the discovery of novel treatments for neurodegenerative disease,” said Professor Julie Frearson, Ph.D., Senior Vice President and Chief Scientific Officer, Charles River. “Logica’s integrated, AI-augmented process allows us to be an agile partner, and combined with Lundbeck’s industry-leading neurology expertise, we look forward to a successful collaboration.” Logica is an Artificial Intelligence powered end-to-end drug discovery solution that translates biological insights into optimized preclinical candidates by leveraging the integration of Valo Health’s AI-powered Opal Computational Platform(TM) and Charles River’s leading expertise in drug discovery and preclinical development. Through the agreement, Lundbeck will deploy Logica with the aim of creating optimized small molecules that lead to novel therapies for neurological research.